1-6 of 6
Kathleen Jentsch-Ulrich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Diagnosis and Treatment of MPN in Real Life - Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Andreas Schmidt, Christiane Bernhardt, Anette Fries, Kathleen Jentsch-Ulrich, Andreas Josting, Stephan Kreher, Marcel Reiser, H. Tilman Steinmetz, Hans Tesch, Bernhard Kaufmann, Uta Rager, Carl C. Crodel, Francesca Palandri, Florian H. Heidel
Journal: Blood
Blood (2022) 140 (Supplement 1): 9698–9699.
https://doi.org/10.1182/blood-2022-157980
Published: 2022
Journal Articles

Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Jesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, Guido Kobbe, Martin Wilhelm, Bernhard Heinrich, Tobias Gaska, Helmut Forstbauer, Burkhard Schmidt, Andreas Hüttmann, Gerhard Heil, Doris M. Kraemer, William Hermann Krüger, Vanja Zeremski, Norbert Grobe, Kathleen Jentsch-Ulrich, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Paul J Bröckelmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 4533.
https://doi.org/10.1182/blood-2021-153200
Published: 2021
Journal Articles

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany

Carl C. Crodel, Kathleen Jentsch-Ulrich, MD, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W. Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, MD, Florian H. Heidel
Journal: Blood
Blood (2019) 134 (Supplement_1): 1672.
https://doi.org/10.1182/blood-2019-122681
Published: 2019
Journal Articles

Imatinib (IM) in Combination with Hydroxyurea Showed Significantly Lower Major Molecular Response Rates at 6 Months but Similar MMR at 18 Months in Patients with CML1st CP Compared to IM Alone. Final Results of the CML2004 Study. NCT 02480608

Thoralf Lange, MD, Rainer Krahl, PhD, Ulrich von Grünhagen, MD, Haifa Kathrin Al-Ali, Schwarzer Andreas, MD, Kathleen Jentsch-Ulrich, MD, Claudia Spohn, MD, Volker Lakner, MD, Michael Assmann, MD, Christian Junghanss, MD, Markus Pfirrmann, Arthur Gil, PhD, Rüdiger Hehlmann, MD, Michael W. Deininger, MD PhD, Dietger Niederwieser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1615.
https://doi.org/10.1182/blood.V130.Suppl_1.1615.1615
Published: 2017
Journal Articles

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Anna Maria Fink, MD, Jasmin Bahlo, PhD, Robrecht Sandra, PhD, Othman Al-Sawaf, MD, Ali Aldaoud, MD, Holger Hebart, MD, Kathleen Jentsch-Ulrich, MD, Steffen Doerfel, Dipl.MD, Kirsten Fischer, Clemens Martin Wendtner, MD, Thomas Noesslinger, MD, Paolo Ghia, MD PhD, Francesc Bosch, MD PhD, Arnon P. Kater, MD PhD, Karl-Anton Kreuzer, Hartmut Dohner, MD, Michael Kneba, Stephan Stilgenbauer, Sebastian Boettcher, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2016) 128 (22): 229.
https://doi.org/10.1182/blood.V128.22.229.229
Published: 2016
Journal Articles

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Barbara Eichhorst, MD, Jasmin Bahlo, Anna Maria Fink, MD, Michael Pfreundschuh, Holger Hebart, MD, Georg Maschmeyer, MD, Kathleen Jentsch-Ulrich, MD PhD, Steffen Dörfel, Anne Westermann, Aline Zey, Kirsten Fischer, Clemens-Martin Wendtner, MD, Thomas Noesslinger, MD, Paolo Ghia, MD PhD, Francesc Bosch, MD PhD, Arnon P. Kater, MD PhD, Karl-Anton Kreuzer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Sebastian Boettcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 4699.
https://doi.org/10.1182/blood.V124.21.4699.4699
Published: 2014